Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : UNO (nitric oxide) is a potent molecule, naturally synthesized in the human body. It is being evaluated in phase 1 clinical trials for advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors.
Brand Name : UNO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 27, 2023
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Avenue Capital Group
Deal Size : Undisclosed
Deal Type : Financing
Beyond Air® Secures up to $40 Million Debt Financing
Details : The financing will be used to support the ongoing commercial launch of LungFit PH (nitric oxide) and advance clinical development of the LungFit platform. The Company has received FDA approval for LungFit PH for persistent pulmonary hypertension of the n...
Brand Name : LungFit
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Avenue Capital Group
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : 7-Nitroindazole
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Hebrew University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Beyond Air gets the commercial rights for multiple neuronal nitric oxide synthase (nNOS) inhibitor candidates, currently being developed for the treatment of autism spectrum disorder (ASD) and other neurological conditions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : 7-Nitroindazole
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Hebrew University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Stanford School of Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Details : Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2023
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Stanford School of Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LungFit PRO (Nitric Oxide) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Brand Name : LungFit PRO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LungFit PRO having nitric oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Brand Name : LungFit PRO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 23, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Beyond Air's LungFit PH Receives FDA Approval for Hypoxic Respiratory Failure
Details : First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide.
Brand Name : LungFit PH
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LungFit® GO is the first Nitric Oxide generator and delivery system safely used in a clinical trial in the home setting with patients self-administering high concentration NO treatment.
Brand Name : LungFit GO
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?